Archives of Clinical Infectious Diseases

Infectious Diseases and Tropical Medicine Research Center, SBUMS

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Publication Ethics and Malpractice Statement Support Contact Us Reviewer and AE Registration Form Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

Crossref

1. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases

- Trinath Chowdhury

- Gourisankar Roymahapatra

- Santi M. Mandal

2. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study

- K. Abraham Peele

- Chandrasai Potla Durthi

- T. Srihansa

- S. Krupanidhi

- Vijaya Sai Ayyagari

- D. John Babu

- M. Indira

- A. Ranganadha Reddy

- T.C. Venkateswarulu

3. SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development

- Guilherme Antonio de Souza Silva

- Suéllen Pedrosa da Silva

- Marcos Aurélio Santos da Costa

- Abdênego Rodrigues da Silva

- Robson Raion de Vasconcelos Alves

- Fernanda das Chagas Ângelo Mendes Tenório

- Alanne Rayssa da Silva Melo

- Antonio Carlos de Freitas

- Cristiane Moutinho Lagos de Melo

4. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report

- Ling Ning

- Lei Liu

- Wenyuan Li

- Hongtao Liu

- Jizhou Wang

- Ziqin Yao

- Shengyu Zhang

- Desheng Zhao

- Björn Nashan

- Aizong Shen

- Lianxin Liu

- Lei Li

5. Classification, structure and mechanism of antiviral polysaccharides derived from edible and medicinal fungus

- Yuxi Guo

- Xuefeng Chen

- Pin Gong

6. Integrating LC–MS/MS and In Silico Methods to Uncover Bioactive Compounds with Lipase Inhibitory Potential in the Antarctic Moss Warnstorfia fontinaliopsis

- Hirotake Yamaguchi

- Ryoichi Yamada

- Kristina Lama

- Ui Joung Youn

- Jun Hyuck Lee

- Tae-Jin Oh

7. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach

- Phulen Sarma

- Manisha Prajapat

- Pramod Avti

- Hardeep Kaur

- Subodh Kumar

- Bikash Medhi

8. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19

- Nils von Hentig

9. Available Antiretrovirals in the Treatment and Pre-Exposure Prophylaxis of SARS-CoV-2: Quo Vadis?

- Miguel Alpalhão

- Paulo Filipe

10. Natural Products as Anti-COVID-19 Agents: An In Silico Study

- Chandan Sarkar

- Sarmin Jamaddar

- Milon Mondal

- Abul Bashar Ripon Khalipha

- Muhammad Torequl Islam

- Mohammad S. Mubarak

11. Targeting COVID-19 pandemic: in silico evaluation of 2-hydroxy-1, 2-diphenylethanone N(4)-methyl-N(4)-phenylthiosemicarbazone as a potential inhibitor of SARS-CoV-2

- Rajan Jeevana

- Abu Pilakkaveettil Kavitha

- Thoppilan G. Abi

- Pookkottu K. Sajith

- Jibin K. Varughese

- Kuttamath Kunniyur Aravindakshan

12. Computational Approaches for Lead Discovery against SARS-CoV-2 3C-Like Protease: Virtual Screening and Molecular Dynamics Studies

- Mohammad Kalim Ahmad Khan

- Feras Almarshad

13. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

- Yu Wai Chen

- Chin-Pang Bennu Yiu

- Kwok-Yin Wong

14. Finding a prospective dual-target drug for the treatment of coronavirus disease by theoretical study

- Karim Mahnam

- Zahra Ghobadi

15. Drug Safety Issues in Therapy COVID-19

- D. G. Levitova

- S. A. Gracheva

- A. S. Samoylov

- U. D. Udalov

- E. A. Praskurnichiy

- O. V. Parinov

16. Safety perspectives on presently considered drugs for the treatment of COVID‐19

- Sophie L. Penman

- Robyn T. Kiy

- Rebecca L. Jensen

- Christopher Beoku‐Betts

- Ana Alfirevic

- David Back

- Saye H. Khoo

- Andrew Owen

- Munir Pirmohamed

- B. Kevin Park

- Xiaoli Meng

- Christopher E. Goldring

- Amy E. Chadwick

17. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

- Michele Costanzo

- Maria Anna Rachele De Giglio

- Giovanni Nicola Roviello

18. Investigating the mechanisms of ethanol-induced disruption of COVID-19 lipid bilayers through molecular dynamics simulations

- Azadeh Kordzadeh

- Ahmad Ramazani SA

19.

20. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment

- Nathan Ford

- Marco Vitoria

- Ajay Rangaraj

- Susan L Norris

- Alexandra Calmy

- Meg Doherty

21. RETRACTED ARTICLE: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

- Yasemin Cag

- Sacit Icten

- Burcu Isik-Goren

- Naciye Betul Baysal

- Begum Bektas

- Ece Selvi

- Pinar Ergen

- Ozlem Aydin

- Ayse Canan Ucisik

- Fatma Yilmaz-Karadag

- Hulya Caskurlu

- Tulin Akarsu-Ayazoglu

- Hasan Kocoglu

- Sinan Uzman

- Muge Nural-Pamukcu

- Ferhat Arslan

- Gurhan Bas

- Mahmut Tayyar Kalcioglu

- Haluk Vahaboglu

22. Potential Pathogenicity Determinants Identified from Structural Proteomics of SARS-CoV and SARS-CoV-2

- Erica T Prates

- Michael R Garvin

- Mirko Pavicic

- Piet Jones

- Manesh Shah

- Omar Demerdash

- B Kirtley Amos

- Armin Geiger

- Daniel Jacobson

- Malik Harmit

23. Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery

- Supriya Roy

- Suneela Dhaneshwar

- Bhavya Bhasin

24. An Overview of COVID-19: Focus on Pharmacological Aspect

- Nandhini Saravanabavan

- Padmavathi Shanmuganathan

- Manimekalai Kumarappan

- Kartik J Salwe

- Barathane Datchanamurthy

- Johan Pandian

- R Sudar Codi

- Vimala Ananthy

- Kamalasundar Thanuskodi

- Uma Narayanamurthy

25. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective

- Simone Perazzolo

- Linxi Zhu

- Weixian Lin

- Alexander Nguyen

- Rodney J.Y. Ho

26. Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction

- Ankita Saha

- Shweta Choudhary

- Priyanshu Walia

- Pravindra Kumar

- Shailly Tomar

27. Potential repurposed SARS-CoV-2 (COVID-19) infection drugs

- Gamal El-Din A. Abuo-Rahma

- Mamdouh F. A. Mohamed

- Tarek S. Ibrahim

- Mai E. Shoman

- Ebtihal Samir

- Rehab M. Abd El-Baky

28. A multiple peptides vaccine against COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the immunoinformatics approach

- Sahar Obi Abd Albagi

- Mosab Yahya Al-Nour

- Mustafa Elhag

- Asaad Tageldein Idris Abdelihalim

- Esraa Musa Haroun

- Mohammed Elmujtba Adam Essa

- Mustafa Abubaker

- Hemchandra Deka

- Arabinda Ghosh

- Mohammed A. Hassan

29. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study

- Nouman Rasool

- Ammara Akhtar

- Waqar Hussain

- Khushbu Gumber

- Pomila

31. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses

- Nakarin Suwannarach

- Jaturong Kumla

- Kanaporn Sujarit

- Thanawat Pattananandecha

- Chalermpong Saenjum

- Saisamorn Lumyong

32. The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course

- N. V. Bobkova

33. COVID-19 and HIV/AIDS in a cohort study in Sao Paulo, Brazil: outcomes and disparities by race and schooling

- S. Q. Rocha

- V. I. Avelino-Silva

- M. V. Tancredi

- L. F. Jamal

- P. R. A. Ferreira

- A. Tayra

- P. M. Ferreira

- T. Carvalhanas

- C. S. B. Domingues

- R. A. Souza

- M. C. Gianna

- A. O. Kalichman

- O. H. M. Leite

- T. N. L. Souza

- D. A. Gomes e Costa

- J. J. D. Furtado

- A. F. Costa

34. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

- Purwati

- Andang Miatmoko

- Nasronudin

- Eryk Hendrianto

- Deya Karsari

- Aristika Dinaryanti

- Nora Ertanti

- Igo Syaiful Ihsan

- Disca Sandyakala Purnama

- Tri Pudy Asmarawati

- Erika Marfiani

- Yulistiani

- Alfian Nur Rosyid

- Prastuti Asta Wulaningrum

- Herley Windo Setiawan

- Imam Siswanto

- Ni Nyoman Tri Puspaningsih

- Mrinmoy Sanyal

35. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India

- Tarun Bhatnagar

- Manoj V. Murhekar

- Manish Soneja

- Nivedita Gupta

- Sidhartha Giri

- Naveet Wig

- Raman Gangakhedkar

36. Therapeutic opportunities of edible antiviral plants for COVID-19

- Bhoomika Patel

- Supriya Sharma

- Nisha Nair

- Jaseela Majeed

- Ramesh K. Goyal

- Mahaveer Dhobi

37. Current pharmacological treatments for COVID‐19: What's next?

- Cristina Scavone

- Simona Brusco

- Michele Bertini

- Liberata Sportiello

- Concetta Rafaniello

- Alice Zoccoli

- Liberato Berrino

- Giorgio Racagni

- Francesco Rossi

- Annalisa Capuano

38. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock

- Dipti Mothay

- K. V. Ramesh

39. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design

- Maria Bzówka

- Karolina Mitusińska

- Agata Raczyńska

- Aleksandra Samol

- Jack A. Tuszyński

- Artur Góra

40. COVID-19: a wreak havoc across the globe

- Heena Rehman

- Md Iftekhar Ahmad

41. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (Mpro) of SARS-CoV-2

- Arabinda Ghosh

- Monoswi Chakraborty

- Anshuman Chandra

- Mohamad Parvez Alam

42. COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach

- Soha R Abd El Hadi

- Esmat E Zien El-Deen

- Mostafa M Bahaa

- Abdelfattah A Sadakah

- Heba A Yassin

43. In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia(giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach

- Papia Chowdhury

44. Screening of potential anti-HIV compounds from Achyranthes aspera extracts for SARS-CoV-2: An insight from molecular docking study

- Tanmoy Dutta

- Sajal Ghorai

- Abdul Ashik Khan

- Nabajyoti Baildya

- Narendra Nath Ghosh

45. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study

- Vanderlan Nogueira Holanda

- Elton Marlon de Araújo Lima

- Welson Vicente da Silva

- Rafael Trindade Maia

- Rafael de Lima Medeiros

- Arabinda Ghosh

- Vera Lúcia de Menezes Lima

- Regina Celia Bressan Queiroz de Figueiredo

46. Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19

- Ekta Shirbhate

- Preeti Patel

- Vijay K Patel

- Ravichandran Veerasamy

- Prabodh C Sharma

- Barij N Sinha

- Harish Rajak

47. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

- Yu Wai Chen

- Chin-Pang Bennu Yiu

- Kwok-Yin Wong

48. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening

- Cristina Adriana Dehelean

- Voichita Lazureanu

- Dorina Coricovac

- Marius Mioc

- Roxana Oancea

- Iasmina Marcovici

- Iulia Pinzaru

- Codruta Soica

- Aristidis M. Tsatsakis

- Octavian Cretu

49. In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19

- Peter Ifeoluwa Adegbola

- Olumide Samuel Fadahunsi

- Aanuoluwa Eunice Adegbola

- Banjo Semire

50. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

- Surjeet Verma

- Danielle Twilley

- Tenille Esmear

- Carel B. Oosthuizen

- Anna-Mari Reid

- Marizé Nel

- Namrita Lall

51. In Silico Investigation of the SARS CoV2 Protease with Thymoquinone, the Major Constituent of Nigella Sativa

- Youness Kadil

- Mohammed Mouhcine

- Houda Filali

52. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

- Bo Ram Beck

- Bonggun Shin

- Yoonjung Choi

- Sungsoo Park

- Keunsoo Kang

53. Biophysics of SARS-CoV-2 spike protein’s receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights

- Fernando Luís Barroso da Silva

- Karen Paco

- Aatto Laaksonen

- Animesh Ray

54. Therapeutic approaches to coronavirus infection according to “One Health” concept

- Giacomo Rossi

- Livio Galosi

- Alessandra Gavazza

- Matteo Cerquetella

- Sara Mangiaterra

55.

56. A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

- Sumel Ashique

- Navjot K. Sandhu

- Sk. Niyamul Haque

- Kartick Koley

57. Identification of Anti-SARS-CoV-2 Compounds from Food Using QSAR-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Analysis

- Magdi E. A. Zaki

- Sami A. Al-Hussain

- Vijay H. Masand

- Siddhartha Akasapu

- Sumit O. Bajaj

- Nahed N. E. El-Sayed

- Arabinda Ghosh

- Israa Lewaa